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transplantation (UCBT) from an unrelated donor after experiencing a life-threatening dissem-
inated Bacillus CalmetteeGue´rin infection. After busulfan and cyclophosphamide condition-
ing, we performed a 5/6-matched UCBT. Engraftment and mixed chimerism was 100% in
peripheral blood, and 100% of his neutrophils had normal oxidative burst activity on day 17.
The patient is now 3 years old, free from infection, and growing well. To our knowledge, this
is the second case of CGD treated with UCBT in Taiwan. His successful outcome illustrates that
UCBT in a patient with CGD should be considered early if a human leukocyte antigen-matched
donor is not available or the patient has just recovered from a severe infection.
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Successful UCBT in an X-linked CGD patient 3471. Introduction
Chronic granulomatous disease (CGD) is a rare inherited
disorder characterized by abnormal functioning of nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase in
phagocyte cells owing to a defect in oxidative killing. Pa-
tients may experience recurrent life-threatening bacterial
and fungal infections. Despite conventional treatment with
prophylactic antibiotic drugs or with interferon gamma, the
long-term survival rate remains poor. Only 50% of patients
reach the age of 30 years.1 Umbilical cord blood trans-
plantation (UCBT) from unrelated donors has been suc-
cessfully used in children with CGD.2 However, there is
limited experience of UCBT in CGD patients, and even less
knowledge about its complete clinical course.
2. Case Report
2.1. Past and family history
The boy was first admitted to the hospital at 6 months of
age because of a spiking temperature for the previous 14
days and multiple small wounds (dimensions, 2  2 cm) with
yellowish discharge on the posterior side of the left thigh,
the anterior side of the right lower leg, the left shoulder,
and at the Bacillus CalmetteeGue´rin (BCG) inoculation site
(Figure 1AeD). His medical history revealed localized axil-
lary lymphadenopathy after a BCG inoculation in infancy
that was under regular antibiotic control. He was the fourth
child born to nonconsanguineous parents; his two elder
brothers had died in early infancy from an unexpected
rapid course of sepsis. The patient’s body weight was 6.2 kg
(<25th percentile), and his height was 64 cm (<10thFigure 1 Multiple small wounds with yellowish discharge on the
right lower leg, (C) the left shoulder, and (D) the BCG inoculation
parahilar areas with peribronchial thickening and overinflatio
(3  2.4  1.9 cm) with necrotic areas and enlarged left cervical
myelitis on the distal third diaphysis and metaphysis of the left hu
destruction with increased signal along the plantar fascia, the dee
lower leg indicates osteomyelitis. BCG Z bacillus CalmetteeGue´ripercentile), and there was no retardation in gross or fine
motor skills or speech development.
Physical examination revealed an elastic, mobile, left
axillary lymph node (3  3  2 cm), with no tenderness
upon palpation and without overlying erythema. On
auscultation, coarse and decreasing breathing sounds with
a fine crackle in the right lung fields were audible. The liver
and spleen were enlarged, tender, and descended by 4 cm
and 3 cm, respectively. A chest radiograph (Figure 1E and F)
revealed pleural effusion and a large consolidation with air
bronchogram in the right lung, and enlarged left axillary
lymph nodes with necrotic change. A magnetic resonance
imaging scan (Figure 1G and H) revealed osteomyelitis
affecting the left humerus associated with septic arthritis
of the elbow joint and the left distal tibia.
Laboratory investigation results were as follows: leuko-
cyte count, 16 103/mL (52.6% neutrophils, 8.3%monocytes,
and 37.0% lymphocytes); hemoglobin level, 11.1 g/dL; and
platelet count, 474  103/mL. Because his oxidative killing
level [measured by flow cytometry with dihydrorhodamine-
123 (DHR-123, Invitrogen, Eugene, USA) oxidation analysis]
was 0%, he was screened for genetic mutations using poly-
merase chain reaction and direct sequencing. Five subunits
of the reduced NADPH oxidase complex were checked: the
X-linked CYBB, which encodes gp91-phox, and autosomal
p22-phox, p47-phox, p67-phox, and p40-phox. A homozygous
c.665A>G (p.H222R) mutation was noted in exon 6 of the
CYBB gene (Figure 2), confirming an X-linked CGD with gp91-
phox deficiency.
2.2. Present history
At 19 months of age, the patient had already received
therapy with voriconazole for more than 1 year to preventposterior side of (A) the left thigh, (B) the anterior side of the
area. (E) Diffused interstitial fluffy opaque shadow of bilateral
n of both lungs. (F) Enlarged left axillary lymph nodes
and right mediastinal and bronchial lymph nodes. (G) Osteo-
merus. (H) Marrow cavity of the calcaneus with focal cortical
p fascia of the ankle joint, and the perivascular sheath of the
n.
Figure 2 The subunits of the reduced NADPH oxidase complex were performed by polymerase chain reaction and direct
sequencing. The c.665A>G (p.H222R) mutation of the CYBB gene in the patient (Pt; A) was compared with the presentation in the
normal population (WT; B) and CGD was confirmed. CGD Z chronic granulomatous disease; NADPH Z nicotinamide adenine
dinucleotide phosphate.
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patients, and ciprofloxacin for suspected BCG-associated or
other bacterial infections. Because no clinical evidence of
active infection was noted in repeated blood cultures and
images, the risks and benefits of hematopoietic stem cell
transplantation were discussed. The parents decided to
proceed with UCBT because his human leukocyte antigen
(HLA) did not match with any of his siblings. An unrelated
HLA-A allele-mismatched cord blood unit was obtained
from the BIONET Cord Blood Bank, Taipei, Taiwan. The HLA
types of the patient were A1101, 3101; B3501, 4001;
DRB10101, and 1101. The HLA types of the donor were
A1101, 1101; B3501, 4001; DRB10101, 1101. The blood type
of the donor was O, and that of the recipient was B. The
preparative regimens consisted of 3.5 mg/kg/day busulfan
(days e9 to e6), 50 mg/kg/day cyclophosphamide (days e5
to e2), and 3 mg/kg/day rabbit antithymocyte globulin
(Thymoglobulin, Genzyme; days e4 to e1). Graft-versus-
host disease (GVHD) prophylaxis comprised cyclosporine A
from day e3 and a short course of methylprednisolone
(1 mg/kg intravenously every 12 hours on days 17e18 thatwas tapered by 25% every day thereafter). The patient
underwent UCBT with total nucleated cells exceeding
14  107/kg, cell viability exceeding 99.62%, and CD34þ
cells exceeding 7  105/kg. Sustained engraftment of
neutrophils exceeded 0.5  103/mL on day 11 and exceeded
1  103/mL on day 16. The self-sustained platelet count
exceeded 20  103/mL on day 24 (October 20, 2011) and
exceeded 50  103/mL on day 58 (November 23, 2011).
Polymerase chain reaction-based chimerism analysis of
peripheral blood revealed complete donor-derived he-
matopoietic chimerism on day 31 (October 27, 2011). The
posttransplant course was complicated by mild fever, and
using anticytomegalovirus monoclonal antibody (Mitsubishi,
Tokyo, Japan), cytomegalovirus was detected in the pa-
tient’s plasma. Intravenous ganciclovir was initiated. Grade
1 acute GVHD involving the skin only was resolved with oral
methylprednisolone. The cyclosporine A dose was gradually
reduced after day 180. Voriconazole and ciprofloxacin were
discontinued 3 months after UCBT, and repeat DHR-123
results (Figure 3) indicated normal activity in all the neu-
trophils after transplantation. The patient is currently free
Figure 3 Dihydrorhodamine-123 (DHR-123) test performed twice before (A series) and after (B series) the patient received cord
blood transplantation. Neutrophils were incubated with DHR-123 and then activated with phorbol myristate acetate. Preactivation
histograms are shown on the left; postactivation histograms are on the right. Blocks A-1 and B-1 show a normal control sample with
a large rightward shift in mean fluorescence intensity. Block A-2 depicts the patient with X-linked CGD lacking a detectable
oxidative burst. Blocks A-3 and B-3 depict the mother of the affected patient with two populations of neutrophilsdone normal and
one with mutated gp91-phox. The histogram in Block B-2 shows the patient neutrophil activity shift to the typical pattern observed
in the normal control after cord blood transplantation. CGD Z chronic granulomatous disease.
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without chronic GVHD.3. Discussion
Two-thirds of all CGD patients possess a mutation in the
X-linked CYBB gene that encodes gp91-phox. Patients with
X-linked CGD have early disease onset and poor prognosis
despite antibiotics or interferon gamma use. The annual
mortality rate is 5% according to the US CGD registry.3 Our
patient belonged to the high-risk group as he presented with
serious pulmonary infections, suspected systemic myco-
bacterium infection, and osteomyelitis in infancy. In view of
poor long-term prognosis and impaired quality of life of CGD
patients, bone marrow transplantation (BMT) should be
considered at an early stage.4 However, we used umbilical
cord blood instead of BMT because the patient had no HLA-
matched siblings and because his sisters were probable
carriers of X-linked CGD. In addition, UCBT was more
appropriate for his small size. Tomohiro et al5 performed
UCBT in seven CGD children. However, a low survival rate
(3/7) was reported, which was probably because UCBT was
selected in five of the patients after the BMT had failed, and
these patients died from severe bacterial or fungal (asper-
gillosis) infections. The disadvantages of UCBT include slow
hematopoietic reconstitution and graft failure, but theseare mostly observed in patients with malignant disorders
than those with benign disease.6 Another study showed that
UCBTcan be curative in CGD patients with rapidly accessible
cord blood and can result in a low incidence and lower
severity of GVHD.7 In Taiwan, 13 children (12 male and 1
female) were diagnosed with CGD (at different hospitals)
from January 1985 to December 2010; among these patients,
the disease courses of eight children have been
described.8e15 Genetic analysis revealed that two of them
had a deficiency of gp91-phox or p47-phox. In five patients,
X-linked CGD was suspected because of a previous family
history of an affected male sibling or because of a finding of
<90% nitroblue tetrazolium-positive neutrophils in their
mothers. Only one patient underwent successful UCBT,13
showing good engraftment, rapid hematological recovery,
and only mild acute GVHD involving the skin.
BCG vaccine is administered worldwide and can have rare
adverse reactions. However, localized axillary lymphade-
nopathy after a BCG inoculation developed in this male pa-
tient in infancy. Attenuated BCG vaccine complications are
common in patients with primary immunodeficiency dis-
eases (PIDs), especially those with profound Tcell deficiency
and CGD. Patients with severe combined T cell and B cell
immunodeficiency are suitable for stem cell trans-
plantation. First, this male infant underwent immunological
evaluations while he had BCG-related diseases. Second, his
family history of two elder siblings’ mortality suggested to
350 C.-J. Lin et althe physicians (obstetricians and neonatologists) that the
child might have an X-linked PID. Thus, prenatal diagnosis
can be made on the basis of family history, and attenuated
vaccine should be avoided in children in such families. All
maternal sisters with a family history of X-linked PIDs should
therefore undergo genetic analysis to confirm whether they
are carriers to enable prenatal diagnosis of their offspring.
Two studies16,17 reported persistent local BCG lymphadenitis
as the initial presentation in CGD patients. Very few studies
have published evidence about whether the incidence of
vaccine strain BCG-induced tuberculosis is high in CGD pa-
tients. The paucity of evidence reflects an ascertainment
bias because tuberculosis is most prevalent in developing
countries where CGD may not be diagnosed.
In conclusion, disseminated mycobacterial BCG infection
is often fatal and results from impaired immunity. We
believe that UCBT is a potential alternative treatment
strategy and may be beneficial for X-linked CGD patients.
Rapid immune reconstitution in CGD patients is particularly
important when recurrent, ongoing life-threatening in-
fections and irreversible organ damage are likely.
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